<DOC>
	<DOC>NCT02050594</DOC>
	<brief_summary>The primary objective of the protocol is to identify and describe observed adverse events (AEs) while on treatment with Ipilimumab for advanced melanoma in Venezuela during the study period</brief_summary>
	<brief_title>Ipilimumab 12-month Intensive Pharmacovigilance Protocol</brief_title>
	<detailed_description />
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com. Age of 18 years or older on date of first dose of Ipilimumab Subjects who received at least 1 dose of Ipilimumab for the treatment of unresectable, recurrent or metastatic melanoma in Venezuela Subjects who received Ipilimumab as part of a clinical trial Subjects who received Ipilimumab for any indication other than local approval (ie, unresectable or metastatic melanoma)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>